Today: 21 March 2026
Subscribe
Browse Category

NASDAQ:MRSN 13 November 2025

Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Day One Biopharmaceuticals will acquire Mersana Therapeutics in a deal valued at up to $285 million, offering $25 per share in cash plus contingent value rights up to $30.25 per share. Mersana’s board and major holders support the agreement. MRSN shares jumped as much as 200% pre-market. Halper Sadeh LLC launched a shareholder fairness investigation.
13 November 2025
···

Stock Market Today

  • MLCAC.PA Falls 7.14% Pre-Market on EURONEXT, Trading Near Year Low
    March 20, 2026, 11:49 PM EDT. MLCAC.PA (Lombard & Medot) opened pre-market at €13.00, down 7.14% on EURONEXT in March 2026, slipping close to its year low of €12.70. Trading volume was extremely light at six shares, underscoring liquidity challenges and potential for price swings. The stock sports a high trailing price-to-earnings (PE) ratio of 92.86 and trades below its 50- and 200-day moving averages, signaling short-term underperformance. Technical indicators show weakness with an RSI of 42.20 and oversold commodity channel index (CCI) at -163.37. Meyka AI assigns a B rating with a HOLD suggestion, projecting a mixed short-term price outlook but 15.61% upside annually. Key risks include illiquidity, high valuation, long inventory days, and dependence on premium Champagne demand in Europe and exports.
Go toTop